ArticleFolia microbiologica2005
Lipopolysaccharide-mediated protection against Klebsiella pneumoniae-induced lobar pneumonia: intranasal vs. intramuscular route of immunization.
Article in Folia microbiologica, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 21 citations in OpenAlex.
- A subunit vaccine against pneumonia: targeting SNetwork modeling and analysis in health informatics and bioinformatics · 2023Article
- FromMicroorganisms · 2021Review
- K-PAM: a unified platform to distinguish Klebsiella species K- and O-antigen types, model antigen structures and identify hypervirulent strains.Scientific reports · 2020Article
- Immunoinformatics-Aided Design and Evaluation of a Potential Multi-Epitope Vaccine againstVaccines · 2019Article
- Evaluation of Recombinant Multi-Epitope Outer Membrane Protein-BasedFrontiers in microbiology · 2017Article
- Depolymerase improves gentamicin efficacy during Klebsiella pneumoniae induced murine infection.BMC infectious diseases · 2014Article
- Identification and characterization of antigens as vaccine candidates against Klebsiella pneumoniae.Human vaccines & immunotherapeutics · 2013Article
- Development of a new trend conjugate vaccine for the prevention of Klebsiella pneumoniae.Infectious disease reports · 2012Review
- Genetic requirements for Klebsiella pneumoniae-induced liver abscess in an oral infection model.Infection and immunity · 2009Article
- Comparison of the host responses to wild-type and cpsB mutant Klebsiella pneumoniae infections.Infection and immunity · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunoprotective potential of delivered lipopolysaccharide (LPS) preparation from Klebsiella pneumoniae was determined in a murine model of lobar pneumonia. Protection was assessed with three doses of LPS (25, 50 and 100 microg; without any adjuvant) administered intranasally or intramuscularly. After evaluation of lung tissue (bacterial load and histopathology), no significant protection was observed at 25 microg with either application. A significant decrease in lung bacterial load coupled with fall in severity of lung lesions was observed with 50 microg (again both applications). At 100 microg dose, with intramuscular route, a further decrease in the lung bacterial load was shown compared to the 50 microg dose. In contrast, 100 microg LPS, when given intranasally, resulted in a higher bacterial colonization of the lung tissue and higher lung pathology; thus we recommend intramuscular instead of the intranasal route for developing protection against K. pneumoniae-mediated pneumonia with intact LPS-based vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.